The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will be offering ‘Focus Panel’ based testing for locally advanced, unresectable, or metastatic urothelial carcinoma (UC) patients, facilitating the on-label use of erdafitinib (Balversa™).
Relevant to this indication, the Focus Panel detects the following alterations:
- FGFR3 Mutations: R248C, S249C, G370C, or Y373C
- FGFR2 Gene Fusions: FGFR2–BICC1, FGFR2–CASP7
- FGFR3 Gene Fusions: FGFR3–TACC3_V1, FGFR3–TACC3_V3, or FGFR3–BAIAP2L1
Individuals with locally advanced, unresectable, or metastatic UC who have experienced disease progression during or after at least one line of prior systemic therapy (including an anti-PD-1 or anti-PD-L1 agent) are eligible for testing. Further details regarding the launch of this test are available in our memo, and additional information about the Focus Panel can be found on the associated webpage.
Testing can be ordered using the CGL Solid Tumour Molecular Requisition, available on our Requisitions page.